Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118867642 | 11886764 | 2 | F | 20160827 | 20160104 | 20160829 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-10236131 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 3.36000 | KG | 20160829 | OT | US | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118867642 | 11886764 | 1 | PS | ZERIT | STAVUDINE | 1 | Oral | 2 MG/KG, QD | U | 20413 | 2 | MG/KG | ORAL SOLUTION | QD | |||||
| 118867642 | 11886764 | 2 | SS | ZERIT | STAVUDINE | 1 | Transplacental | UNK | U | 20413 | ORAL SOLUTION | ||||||||
| 118867642 | 11886764 | 3 | SS | ZERIT | STAVUDINE | 1 | Transplacental | U | 20413 | ORAL SOLUTION | |||||||||
| 118867642 | 11886764 | 4 | SS | EPIVIR | LAMIVUDINE | 1 | Oral | 4 MG/KG, QD | U | 0 | 4 | MG/KG | QD | ||||||
| 118867642 | 11886764 | 5 | SS | EPIVIR | LAMIVUDINE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118867642 | 11886764 | 6 | SS | EPIVIR | LAMIVUDINE | 1 | Transplacental | U | 0 | ||||||||||
| 118867642 | 11886764 | 7 | SS | VIRAMUNE | NEVIRAPINE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118867642 | 11886764 | 8 | SS | NELFINAVIR MESYLATE | NELFINAVIR MESYLATE | 1 | Transplacental | U | 0 | ||||||||||
| 118867642 | 11886764 | 9 | SS | RETROVIR | ZIDOVUDINE | 1 | Oral | UNK | U | 0 | |||||||||
| 118867642 | 11886764 | 10 | SS | RETROVIR | ZIDOVUDINE | 1 | Transplacental | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118867642 | 11886764 | 1 | Prophylaxis against HIV infection |
| 118867642 | 11886764 | 3 | Product used for unknown indication |
| 118867642 | 11886764 | 4 | Prophylaxis against HIV infection |
| 118867642 | 11886764 | 6 | Product used for unknown indication |
| 118867642 | 11886764 | 7 | Product used for unknown indication |
| 118867642 | 11886764 | 8 | Product used for unknown indication |
| 118867642 | 11886764 | 9 | Prophylaxis against HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118867642 | 11886764 | OT |
| 118867642 | 11886764 | HO |
| 118867642 | 11886764 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118867642 | 11886764 | Anaemia | |
| 118867642 | 11886764 | Blood lactic acid increased | |
| 118867642 | 11886764 | Cholinergic syndrome | |
| 118867642 | 11886764 | Failure to thrive | |
| 118867642 | 11886764 | Foetal exposure during pregnancy | |
| 118867642 | 11886764 | Hypertriglyceridaemia | |
| 118867642 | 11886764 | Mean cell volume increased | |
| 118867642 | 11886764 | Neutropenia | |
| 118867642 | 11886764 | Platelet count increased | |
| 118867642 | 11886764 | Sickle cell anaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |